



# Announcing a giant leap forward in IOL evolution

As you would expect from an IOL evolved from the trusted PMMA family, **AcrySof®** offers some very important advantages.

**AcrySof®** has demonstrated a very low intraocular foreign-body response compared to silicone and PMMA.

**AcrySof®** offers enhanced patient satisfaction and reduced costs as a result of the low rate of posterior capsular opacification.

**AcrySof®** is highly resistant to YAG breakdown, helping to maintain optical resolution after Nd:YAG exposure.

## And it folds too

PMMA  
(Monoflex®)  
haptics give  
excellent  
centration



**AcrySof®**  
gives good  
surgical  
control

**ACRY** Sof®  
SOFT ACRYLIC IOL



Alcon Laboratories (UK) Ltd., Pentagon Park, Boundary Way, Hemel Hempstead, Herts. HP2 7UD. Tel: (01442) 341234 Fax: (01442) 341200

Customer Service Dept.

Tel: (01442) 341311, 341321, 341331, 341341 Fax: (01442) 341250

® denotes registered trademark of Alcon Laboratories.



GR 24803 Metamorphosis of Narcissus by Dalí, Salvador (1904-89) Tate Gallery, London/Bridgeman Art Library, London.  
Metamorphosis of Narcissus by Salvador Dalí 1937 © DEMART PRO ARTE BV/DACS 1996

# The more you look at Teoptic, the more you see

On the face of it, one topical  $\beta$ -blocker can seem much like all the others. Look further and Teoptic's advantage begins to emerge:

- IOP is effectively lowered.
- Teoptic may improve ocular perfusion<sup>1,2</sup> and may offer protection of visual fields.<sup>3</sup>
- Teoptic has ISA which may reduce the incidence of systemic adverse events.<sup>4</sup>
- Teoptic is comfortable in the eye<sup>5</sup>, which may lead to good patient compliance.
- as the least expensive  $\beta$ -blocker around, it offers substantial savings to hospital and community.<sup>6</sup>

If you try it, you could see glaucoma treatment from an entirely new perspective.

**ISA**  
**teoptic**  
carteolol hydrochloride

#### Teoptic® Abridged Prescribing Information

**Presentation:** Eye drops containing carteolol hydrochloride 1% or 2% w/v. Preservative 0.005% benzalkonium chloride. **Uses:** Topical treatment for the reduction of intraocular pressure. **Dosage and Administration:** *Adults:* one drop of Teoptic 1% in affected eye twice daily. If required, dosage may be increased to Teoptic 2% twice daily. *Children:* Use not recommended. *Elderly:* Dosage as for adults. **Contra-indications:** Uncontrolled cardiac insufficiency, bronchospasm, bronchial asthma, chronic obstructive airways disease, pregnancy, hypersensitivity. **Precautions:** Use with caution

and in patients already receiving systemic beta-blockers or any medication known to interact with systemic beta-blockers. Soft contact lenses should not be worn. **Side Effects:** Occasional ocular reactions, corneal disorders, bradycardia, bronchospasm, rashes, dyspnoea, headache, lassitude and vertigo. **Breast Feeding:** Teoptic may penetrate the breast milk. Use should therefore be at the discretion of the physician. **Product Licence Numbers:** Teoptic 1%: 8685/0005. Teoptic 2%: 8685/0006. **Product Authorisation Numbers:** Teoptic 1%: 582/10/1. Teoptic 2%: 582/10/2. **Product Licence Holder/Product Authorisation Holder:** CIBA Vision

21.G. Further information is available on request. **Basic NHS price:** 1% £4.83, 2% £5.67. **Basic GMS price:** 1% IR£5.07, 2% IR£5.59. Teoptic is under licence from Otsuka, Japan. Teoptic is a registered trademark. **Date of Preparation:** November 1995. Ref: CVO 236. **References:** 1. Chris P, Sorkin EM. *Drugs and Aging*, 1992;2:58-77. 2. Mihara M. *Ther Res*, 1989;10(10):161-167. 3. Boles-Carenini B *et al.* *New Trends in Ophthalmology*, 1991;6:No2,109-119. 4. Zimmerman TJ. *Journal of Ocular Pharmacology*, 1993;9:No4,373-384. 5. Schnarr K. *Klin. Mbl. Augenheilk.*, 1988;192:167-172. 6. Chemist and **CIBAVision®**